December 9, 2024 I Paris, France EnnoDC, a clinical-stage biotech company pioneering the design and development of first-in-class Dendritic Cell-targeting…
Read More
October 2, 2024 I Paris, France Provides important validation of the safety and immunogenicity of EnnoDC’s technology The ANRS VRI06…
Read More
September 26, 2024 I Paris, France Versatile new technology featuring an antibody fused with an antigen, harnesses the power of…
Read More
September 18, 2023 I Paris, France LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the…
Read More
July, 20 2023 I Paris – Toulouse PanCov is born from a collaboration with French GTP BIOWAYS and European FAREVA…
Read More
22 February 2023 I Paris First vaccine to target dendritic cells, key activators of the immune system Novel delivery of…
Read More
19 January, 2023 I Paris, France CD40HVac is a therapeutic vaccine candidate in immuno-oncology targeting dendritic cells LinKinVax, a clinical-stage…
Read More
9th January, 2023 I Paris LinKinVax, a clinical-stage biotechnology company is announcing capital funding for a total of €7,3 M from…
Read More
10th February, 2022 I Paris LinKinVax, a clinical-stage biotechnology company is announcing completion of a €4.350 million seed capital funding round.…
Read More
3rd February, 2022 I Paris LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with…
Read More
